OptiBiotix Health PLC logo

OptiBiotix Health PLC (OPTI)

Market Closed
12 Aug, 15:30
LSE LSE
5. 75
GBX
0
0%
GBX
15.18M Market Cap
- P/E Ratio
- Div Yield
64,528 Volume
- Eps
5.75 GBX
Previous Close
Add Transaction
Day Range
5.62 5.97
Year Range
4.5 13.5
Want to track OPTI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

OPTI closed today higher at 5.75 GBX, an increase of 0% from yesterday's close, completing a monthly decrease of -10.1563% or -0.65 GBX. Over the past 12 months, OPTI stock lost -14.8148%.
OPTI is not paying dividends to its shareholders.
The last earnings report, released on Sep 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
OptiBiotix Health PLC has completed 1 stock splits, with the recent split occurring on Aug 05, 2014.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

OPTI Chart

People also search for

Eden Research PLC
2.3 GBX
-6.1224%
OBI
Ondine Biomedical Inc.
13.75 GBX
0%
OBD
Oxford Biodynamics Plc
0.13 GBX
+4%
IXI
Ixico plc
7.5 GBX
+3.4483%
FAB
Fusion Antibodies Ltd.
10.5 GBX
0%

OptiBiotix Health PLC (OPTI) FAQ

What is the stock price today?

The current price is 5.75 GBX.

On which exchange is it traded?

OptiBiotix Health PLC is listed on LSE.

What is its stock symbol?

The ticker symbol is OPTI.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 15.18M.

Has OptiBiotix Health PLC ever had a stock split?

OptiBiotix Health PLC had 1 splits and the recent split was on Aug 05, 2014.

OptiBiotix Health PLC Profile

Biotechnology Industry
Healthcare Sector
Mr. Stephen Patrick O'Hara CEO
LSE Exchange
GB00BP0RTP38 ISIN
United Kingdom Country
10 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

OptiBiotix Health Plc is a UK-based life sciences company that operates on a global scale, including in the United States, China, and other international markets. Founded in 2006 and originally known as Ducat Ventures PLC until its name change in August 2014, the company specializes in the discovery and development of microbiome modulators. These are designed to interact beneficially with the human microbiome—the collection of all the microorganisms living in association with the human body—to improve health and wellbeing. OptiBiotix focuses on creating microbial strains, compounds, and formulations that can be integrated into food ingredients, supplements, and active compounds. These products aim to impact human physiology positively and provide potential health benefits, specifically targeting the prevention and management of chronic lifestyle disorders such as obesity, hypercholesterolemia, and diabetes. Headquartered in York, United Kingdom, OptiBiotix is at the forefront of leveraging microbiome science to bring innovative health solutions to the global market.

Products and Services

  • Slimbiome

    An innovative weight management system designed to help maintain a healthy weight in a hunger-free manner. Utilizing a scientifically formulated blend of ingredients, Slimbiome promotes feelings of fullness, helps control cravings, and supports metabolism for sustainable weight management.

  • SlimBiome Medical

    A natural supplement aimed at supporting weight management. SlimBiome Medical uses a unique formulation to support dietary management efforts, facilitating easier and more manageable weight loss journeys for individuals seeking a natural approach.

  • Lactobacillus plantarum LPLDL

    A specially identified probiotic strain designed to aid cardiovascular health and overall wellbeing. Lactobacillus plantarum LPLDL can help manage cholesterol levels and promote heart health, demonstrating OptiBiotix's commitment to leveraging beneficial bacteria for physical health improvements.

  • CholBiome

    A targeted food supplement designed for the reduction of cholesterol and blood pressure levels. CholBiome uses a synergistic blend of ingredients to support cardiovascular health, addressing some of the primary factors associated with heart disease.

  • LPGOS

    A type of galactooligosaccharide used in various food products and applications. LPGOS is known for its prebiotic properties, supporting gut health, reducing cardiovascular risk factors, and enhancing overall health through improved digestive well-being.

  • Sweetbiotix

    A revolutionary low-calorie sweetener designed for use in food and beverages. Sweetbiotix offers the sweet taste consumers enjoy without the added calories, enabling healthier diet choices without sacrificing flavor, illustrating OptiBiotix's innovation in food ingredient development.

Contact Information

Address: Innovation Centre
Phone: -